Cardax, Inc. (CDXI)
0.0001
0.00 (0.00%)
USD |
OTCM |
Jan 16, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.0001M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 9.90K% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.0% |
Profile
| Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The firm focuses on astaxanthin, a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories. Its product platform includes pharmaceutical candidates CDX-101 and CDX-301, and dietary supplement, ZanthoSyn. The company was founded on February 7, 2014 and is headquartered in Honolulu, HI. |
| URL | http://www.cardaxpharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Hawaii |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The firm focuses on astaxanthin, a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories. Its product platform includes pharmaceutical candidates CDX-101 and CDX-301, and dietary supplement, ZanthoSyn. The company was founded on February 7, 2014 and is headquartered in Honolulu, HI. |
| URL | http://www.cardaxpharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Hawaii |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |